CHCWM – Cancer & Hematology Centers of West Michigan

eFT226-0002 (Effector Therapeutics)

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Intravenous Zotatifin (eFT226) in Subjects with Selected Advanced Solid Tumor Malignancies